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Summary There is no information on the effect of food or concurrent drug administration on the bioavailability of oral etoposide, despite the fact that treatment is frequently administered over several days and most often in combination with other cytotoxic agents. The influence of these factors has been studied in 11 patients, receiving combination cytotoxic therapy for extensive small cell lung carcinoma. Neither food nor concurrent oral or intravenous chemotherapy had a significant effect on the mean plasma concentrations of etoposide, achieved following oral administration. Wide variation in peak plasma concentrations and in area under the concentration*time curve (AUC) occurred both between and within patients. It appears unnecessary for patients receiving etoposide (at 100mg) to fast prior to drug administration. Furthermore, oral etoposide (at 100mg and at 400mg) may be given in combination with other cytotoxic agents without compromising its bioavailability.
Etoposide was introduced into clinical trials in the early 1970s (Issell, 1982) and is established in the treatment of several malignancies, including small cell lung cancer, germ cell tumours and lymphomas (Arnold, 1979; Issell & Crooke, 1979; Vogelzang et al., 1982) .
The demonstration of schedule dependency in both experimental systems (Dombernowsky & Nissen, 1973; Rozencweig et al., 1977; D'Incalci & Garattini, 1982) and possibly also in man (Cavalli et al., 1978; Pedersen & Hansen, 1983 ) has led to most schedules of therapy being given over several (usually 3-5) days (Arnold, 1979; Nissen et al., 1980; Issell, 1982) .
The bioavailability of the oral etoposide capsule has been shown to be approximately 50% but with large variation between patients Harvey et al., 1984a) . Despite the widespread use of oral etoposide over 3-5 days and its predominant use as part of combination chemotherapy regimens (Arnold, 1979; Comis, 1982; Rivera et al., 1982; Williams & Einhorn, 1982) , there are no data concerning the influence of food or other chemotherapy on etoposide bioavailability.
The intestinal absorption of some drugs has been shown to be affected by both food (Melander, 1978; McLean et al., 1978; Pinkerton et al., 1980) and chemotherapy (Pinkerton et al., 1982) . The effect of food and concomitant oral and intravenous chemotherapy on the bioavailability of etoposide has therefore been studied. 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12 and 24h. Blood samples were taken into lithium/heparin tubes separated and stored at -20°C until assay. Urine was collected following etoposide administration for 24 h. The total daily quantity was measured and an aliquot taken and stored at -20°C until assay. One patient was unable to collect his urine reliably and these specimens were discarded.
Assay was performed using reverse phase high performance liquid chromatography with detection by ultra violet absorbance at 229 nm as previously described (Harvey et al., 1985) . The lower limit of sensitivity was <100 ng ml -1 and coefficients of variation were <4% within-run and <7% between-run.
Calculation and statistics
Pharmacokinetic profiles were plotted using Stripe (Johnston & Woollard, 1983) Figure 2 . Despite considerable variation within patients in both peak plasma concentrations and AUC, neither consistent increase or decrease was shown. The variation seen over 3 days was no greater than that following repeated oral administration without concurrent chemotherapy (Slevin et al., 1983) . Thus intravenous adriamycin and oral procarbazine did not significantly affect the bioavailability of etoposide.
Discussion
The bioavailability of oral etoposide shows considerable variation between patients (D'Incalci et Harvey et al., 1984a) and, at least at higher doses, variation within patients is also significant (Slevin et al., 1983) . There are several studies of the bioavailability of etoposide following single doses in the fasting state (Beveridge et al., 1976; Lawrie et al., 1982; Slevin et al., 1983; Harvey et al., 1984a Harvey et al., , 1985 but despite its frequent use in schedules of treatment combined with other drugs and spread over several days (Arnold, 1979; Nissen et al., 1980; Comis, 1982; Issell, 1982) , there are no previous data on the effect of either concomitant chemotherapeutic agents or of food on etoposide bioavailability.
The interaction of food and drugs is complex and may lead to an increase, a decrease or no change in the bioavailability of the drug (Melander, 1978) .
The interaction may be mediated via a variety of mechanisms, including drug reaction with specific food substances, delayed gastric emptying, alteration in the rates of tablet/capsule dissolution and altered first-pass metabolism either by an effect directly on hepatic enzymes or on hepatic blood flow (Melander, 1978; McLean et al., 1978) . A combination of these factors may produce contrasting effects on the absorption of drugs of similar chemical composition or even in different preparations of the same drug (Welling & Tse, 1982) . Such complex possibilities make predictions impossible and only by direct studies on the drug concerned can the question be resolved (Melander, 1978; Welling & Tse, 1982) .
The effect of cytotoxic chemotherapy on intestinal absorption has been infrequently studied, despite the common use of drugs in combinations (Zubrod, 1980) and a low therapeutic ratio, which make any interaction potentially serious (Prescott, 1980) . Methotrexate is one of the few cytotoxic drugs studied. It has been shown to impair xylose absorption but not its own absorption, following both single and repeated doses (Pinkerton et al., 1981) .
The data shown here suggest that, at least at doses of 100mg, food does not significantly interfere with etoposide bioavailability and it is probably unnecessary for patients to fast prior to etoposide administration. This is of particular importance, because it is possible that administration in divided doses may be more efficacious than in a single dose as is the case in experimental systems (Dombernowsky & Nissen, 1973; Rozencweig et al., 1977; D'Incalci & Garattini, 1982) and possibly man (Cavalli et al., 1978; Pedersen & Hansen, 1983) .
Neither concomitant oral chemotherapy with cyclophosphamide and methotrexate at low doses, nor simultaneous treatment with intravenous adriamycin together with oral procarbazine were shown to affect etoposide bioavailability in a consistent manner. There were considerable changes in AUC with food and concurrent chemotherapy in some patients, but these were no greater than the variation within patients following repeated oral etoposide in the absence of concomitant chemotherapy (Slevin et al., 1983) . Thus it appears that oral etoposide may be safely given as part of a combination chemotherapy regimen without compromising its bioavailability.
The marked variation in bioavailability both between and within patients observed in this and other studies appears to be due to factors other than food and concomitant chemotherapy.
